During the past decade, Complexo Hospitalario Universitario de Ourense conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 5 clinical trials were completed, i.e. on average, 7.1% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 4 clinical trials were completed. i.e. 8.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Complexo Hospitalario Universitario de Ourense" #1 sponsor was "Spanish Oncology Genito-Urinary Group" with 7 trials, followed by "Fundacin Biomedica Galicia Sur" with 6 trials sponsored, "Celgene" with 5 trials sponsored, "Amgen" with 4 trials sponsored and "PETHEMA Foundation" with 4 trials sponsored. Other sponsors include 58 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Complexo Hospitalario Universitario de Ourense" #1 collaborator was "Dynamic Science S.L." with 3 trials as a collaborator, "Galician South Health Research Institute" with 3 trials as a collaborator, "Instituto de Salud Carlos III" with 3 trials as a collaborator, "Apices Soluciones S.L." with 2 trials as a collaborator and "Astellas Pharma Inc" with 2 trials as a collaborator. Other collaborators include 86 different institutions and companies that were collaborators in the rest 84 trials.

According to Clinical.Site data, the most researched conditions in "Complexo Hospitalario Universitario de Ourense" are "Colorectal Cancer" (4 trials), "Multiple Myeloma" (4 trials), "Breast Cancer" (3 trials), "COVID-19" (3 trials) and "Gastric Cancer" (3 trials). Many other conditions were trialed in "Complexo Hospitalario Universitario de Ourense" in a lesser frequency.

Most popular intervention types in "Complexo Hospitalario Universitario de Ourense" are "Drug" (47 trials), "Other" (16 trials), "Device" (7 trials), "Biological" (6 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Lenalidomide" (3 trials) and "Abelacimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Complexo Hospitalario Universitario de Ourense" are 80 trials for "All" genders, 5 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Complexo Hospitalario Universitario de Ourense". 5 are not yet recruiting, 23 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Complexo Hospitalario Universitario de Ourense, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Complexo Hospitalario Universitario de Ourense, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 12 trials that are defined as “Not Applicable".

Complexo Hospitalario Universitario de Ourense has several departments that took part in Clinical trials: "Hospital Lucus Augusti; Servicio de Oncologia" - 15 trials, "Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría" - 4 trials, "Complejo Hospitalario Universitario de Ourense, Servicio de Hematologia" - 2 trials